Navigation Links
Cellectar Expands Clinical Management Team
Date:10/3/2007

- Appoints Director, Clinical Operations and Manager, Medical Affairs -

MADISON, Wis., Oct. 3 /PRNewswire/ -- Cellectar LLC, (Cellectar), a privately-held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, today announced the appointment of Ernest Allen as Director, Clinical Operations and LisaAnn Trembath as Manager of Medical Affairs. These appointments reflect the advancement of the company's lead product, CLR1404, toward clinical trials.

Prior to joining Cellectar, Mr. Allen spent over 20 years in progressively senior positions in clinical operations for pharmaceutical companies including Alcon, Amgen, Parke-Davis and Origin Pharmaceuticals, Inc., a U.K.-based Clinical Research Organization (CRO), where he served as Senior Clinical Manager. Most recently, he was Clinical Manager for Tapestry Pharmaceuticals, Inc., a cancer treatment pharmaceutical company located in Boulder, CO.

Ms. Trembath brings 21 years of experience as a nuclear medicine technologist specializing in medical imaging, including 10 years of clinical trials research experience and nine years in the radiopharmaceuticals industry. Immediately prior to joining Cellectar, Ms. Trembath was a Senior Clinical Affairs Specialist in the Medical Affairs Division at Bristol-Myers Squibb Medical Imaging, where she developed tools and educational programs for partner clinicians and field personnel. Prior to her position at BMS, she coordinated clinical trials research at the Medical College of Wisconsin and project management at Affiliated Research Centers.

Bill Clarke, M.D., Cellectar's President and CEO, commented, "As we advance our lead product candidate, CLR1404, toward clinical trials, Ernest and LisaAnn bring the necessary clinical development skills needed for our progression. These highly experienced individuals are excellent additions to our team."

CLR1404 is currently in preclinical development and the co
'/>"/>

SOURCE Cellectar LLC
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. PromegaExpress Expands Easy Access to Products with New Cabinet
2. Genetic Analysis Systems Enter the Clinical Mainstream
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2008)...NAA says: Wrong Question Asked. Wrong Children Stu.... 3 /PRNewswire-USNewswire/ -- A Centers for Disea...ay claims there is no link,between the MMR vaccine...,says this study does nothing to dispel the growin...and raises several questions concerning design,and...
(Date:9/3/2008)... - Long term follow up results from chronically in...xceed positive data obtained earlier in 2008, - ...cant and long-term antiviral effect of ther... way and strongly support move into a second gener...nt IC31(R) acting through TLR ...
(Date:9/3/2008)... GAITHERSBURG, Md., Sept. 3 /- Panace...ce of U.S. Patent Number 7,413,737 covering,antibo...roxylase (HAAH), a,proprietary human cancer biomar...developed in collaboration with the Massachusetts ...usive, worldwide rights to this patent,for develop...
(Date:9/3/2008)... Company Focuses Operations, Updates Zingo Launch ...ation Strategy Conference Call To...Sept. 3 /- Anesiva,Inc. (N...ll restructure,operations to focus on commercial a...s transition to a specialty pharmaceutical pain ma...
Breaking Medicine Technology:CDC Misses Target With Flawed MMR/Autism Study 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5ZONARE Names Marcotte Chief Financial Officer 4588 1ZONARE Names Marcotte Chief Financial Officer 4588 2New Survey Shows Majority of Employers Rank Smoking as One of Their Greatest Priority Health Issues But Only 2 Percent Provide Comprehensive Smoking 4584 1New Survey Shows Majority of Employers Rank Smoking as One of Their Greatest Priority Health Issues But Only 2 Percent Provide Comprehensive Smoking 4584 2New Survey Shows Majority of Employers Rank Smoking as One of Their Greatest Priority Health Issues But Only 2 Percent Provide Comprehensive Smoking 4584 3New Survey Shows Majority of Employers Rank Smoking as One of Their Greatest Priority Health Issues But Only 2 Percent Provide Comprehensive Smoking 4584 4New Survey Shows Majority of Employers Rank Smoking as One of Their Greatest Priority Health Issues But Only 2 Percent Provide Comprehensive Smoking 4584 5Leading Edge Research Underway in Fall Prevention for Seniors 1502 1Leading Edge Research Underway in Fall Prevention for Seniors 1502 2Leading Edge Research Underway in Fall Prevention for Seniors 1502 3Genzyme and Sunway to Collaborate on Gene Therapy Program in China 1498 1Genzyme and Sunway to Collaborate on Gene Therapy Program in China 1498 2Genzyme and Sunway to Collaborate on Gene Therapy Program in China 1498 3Genzyme and Sunway to Collaborate on Gene Therapy Program in China 1498 4
...age of More Than Two Hours Per Day, RESEARCH TRIAN...ing the once daily, investigational medication REQ...lease Tablets to,Parkinson,s patients, existing le..., time, allowing patients to continue,their daily ...,describes the return of Parkinson,s symptoms as a...
...ppresses Amyloid Plaque Formation, ANNAPOLIS, Md.,... a leading biodefense company specializing in the ...ermeasures against chemical,and biological terrori...nant butyrylcholinesterase (rBChE) research progra... Conference on,Alzheimer,s and Parkinson,s Disease...
Other Medicine Technology:Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 2Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 3Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 4Once Daily, Extended-Release Ropinirole Improves Parkinson's,Symptoms in Patients not Optimally Controlled With Levodopa 5PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 2PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 3PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 4PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 5PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 6
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...on is putting his best foot forward with respect t...ions are rife for the parties’ annual spring// con...terated that curtailing health problems like obesi...and the risk of sexually transmitted diseases is v...
...ch age of modern medicine, could it be possible to...ugh the power //of meditation? According to a stud...technique can significantly reduce the severity of...lts of this study indicate that transcendental med...
... insulin therapy on the medical-surgical wards res...dividualized management// in patients with diabeti...may be possible. “This is the first randomized ... subcutaneous insulin protocol on medical-surgical...
...c, which is present in every part of the body, cou...study that could help// in the development of new ...ribute to the formation of plaques in the brains o... disease. It is also vital for the healthy working...
Other Medicine News:Health News:Transcendental Meditation Can Help 2Health News:New Research May Pave the Way for Shorter Hospital Stays for Diabetes Patients 2
The HYRYS™ 2 densitometer is reflective of Sebia's expertise in the development and design of imaging systems and densitometers utilized in the electrophoresis field.
Hydragel K20 is Sebia's quality line of manual agarose gel electrophoresis products. Samples are applied utilizing the same patented applicator combs that is used for sample application on the HYDRAS
Eliminating the need for any manual pipetting, the HydraPLUS delivers precise micro-volumes of sample directly from primary tubes to four HYDRASYS sample applicators contained in a built-in humidity
Handheld Digital Retinal Camera
Medicine Products: